Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoVEVax
- Development stage
- Preclinical
- Lead developer
- Ciloa
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal, Inhalation
01
Overview
CoVEVax is a preclinical-stage pan-coronavirus vaccine candidate developed by Ciloa. It utilizes a proprietary small extracellular vesicle (sEV) platform where the SARS-CoV-2 Spike protein is fused to a "Pilot Peptide" and displayed on the surface of the sEVs. This approach is designed to induce a robust antiviral immune response against SARS-CoV-2 and potentially other coronaviruses by presenting the antigen in a natural, membrane-bound conformation to enhance immunogenicity.
- Brand names
- CoVEVax
- Other names
- SARS-CoV-2 vaccineSARS-CoV2 vaccineSARS-CoV 2 vaccinepan-coronavirus vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)SARS-CoV-2 spike glycoprotein (displayed on extracellular vesicles)SARS-CoV-2 spike
Beyond the preview
Go deeper on CoVEVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoVEVax.